WO2008156094A1 - ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 - Google Patents
ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 Download PDFInfo
- Publication number
- WO2008156094A1 WO2008156094A1 PCT/JP2008/061087 JP2008061087W WO2008156094A1 WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1 JP 2008061087 W JP2008061087 W JP 2008061087W WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- active ingredient
- inhibitor containing
- pyridazinone derivative
- pde inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002692248A CA2692248A1 (en) | 2007-06-19 | 2008-06-18 | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
EP08765704A EP2168959A1 (en) | 2007-06-19 | 2008-06-18 | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
US12/452,172 US20100160335A1 (en) | 2007-06-19 | 2008-06-18 | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
JP2009520496A JPWO2008156094A1 (ja) | 2007-06-19 | 2008-06-18 | ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-160955 | 2007-06-19 | ||
JP2007160955 | 2007-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008156094A1 true WO2008156094A1 (ja) | 2008-12-24 |
Family
ID=40156253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/061087 WO2008156094A1 (ja) | 2007-06-19 | 2008-06-18 | ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100160335A1 (ja) |
EP (1) | EP2168959A1 (ja) |
JP (1) | JPWO2008156094A1 (ja) |
CA (1) | CA2692248A1 (ja) |
WO (1) | WO2008156094A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010117926A1 (en) * | 2009-04-07 | 2010-10-14 | Schering Corporation | Substituted triazolopyridines and analogs thereof |
JP2012512192A (ja) * | 2008-12-19 | 2012-05-31 | レオ ファーマ アクティーゼルスカブ | 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体 |
EP2719686A1 (en) * | 2010-03-12 | 2014-04-16 | Nippon Soda Co., Ltd. | Process to halogenate a picoline derivative |
JP2019506432A (ja) * | 2016-03-04 | 2019-03-07 | 大塚製薬株式会社 | 5−メチル−6−フェニル−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2492263A1 (en) * | 2006-07-25 | 2012-08-29 | Cephalon, Inc. | Pyridizinone Derivatives |
DK2430014T3 (en) * | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
BR112013019893A2 (pt) | 2011-02-03 | 2016-10-11 | Lupin Ltd | derivados de pirrol usados como moduladores de alfa7 nachr |
EP2691368A1 (en) | 2011-03-31 | 2014-02-05 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
CN104478809B (zh) * | 2014-11-14 | 2016-08-17 | 成都新恒创药业有限公司 | 一种左西孟旦杂质及其制备和检测方法 |
CN104530113A (zh) * | 2014-12-22 | 2015-04-22 | 上海树农化工有限公司 | 邻氟苯甲酸类化合物及其制备方法 |
CN106938985B (zh) * | 2016-08-31 | 2020-05-05 | 湖南大学 | 一种5-位烯基化8-酰胺基喹啉类化合物及其一锅法制备方法 |
CN106905233A (zh) * | 2016-08-31 | 2017-06-30 | 湖南大学 | 一种5‑位炔基化8‑酰胺基喹啉类化合物及其一锅法制备方法 |
CN106938984B (zh) * | 2016-08-31 | 2020-05-05 | 湖南大学 | 一种5-位取代芳基化/杂环化8-酰胺基喹啉类化合物及其一锅法制备方法 |
EP4341266A1 (en) | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095666A1 (ja) * | 2005-03-07 | 2006-09-14 | Kyorin Pharmaceutical Co., Ltd. | ピラゾロピリジン-4-イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤 |
JP2007119397A (ja) * | 2005-10-28 | 2007-05-17 | Kyorin Pharmaceut Co Ltd | ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤 |
JP2008024599A (ja) * | 2006-07-18 | 2008-02-07 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体、それらを有効成分とするpde阻害剤及び医薬 |
WO2008029882A1 (fr) * | 2006-09-07 | 2008-03-13 | Kyorin Pharmaceutical Co., Ltd. | Dérivé de 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone, sel d'addition de celui-ci et inhibiteur de la pde comprenant le dérivé ou le sel en tant que matière active |
JP2008063265A (ja) * | 2006-09-06 | 2008-03-21 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 |
-
2008
- 2008-06-18 US US12/452,172 patent/US20100160335A1/en not_active Abandoned
- 2008-06-18 CA CA002692248A patent/CA2692248A1/en not_active Abandoned
- 2008-06-18 JP JP2009520496A patent/JPWO2008156094A1/ja active Pending
- 2008-06-18 EP EP08765704A patent/EP2168959A1/en not_active Withdrawn
- 2008-06-18 WO PCT/JP2008/061087 patent/WO2008156094A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095666A1 (ja) * | 2005-03-07 | 2006-09-14 | Kyorin Pharmaceutical Co., Ltd. | ピラゾロピリジン-4-イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤 |
JP2007119397A (ja) * | 2005-10-28 | 2007-05-17 | Kyorin Pharmaceut Co Ltd | ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤 |
JP2008024599A (ja) * | 2006-07-18 | 2008-02-07 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体、それらを有効成分とするpde阻害剤及び医薬 |
JP2008063265A (ja) * | 2006-09-06 | 2008-03-21 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 |
WO2008029882A1 (fr) * | 2006-09-07 | 2008-03-13 | Kyorin Pharmaceutical Co., Ltd. | Dérivé de 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone, sel d'addition de celui-ci et inhibiteur de la pde comprenant le dérivé ou le sel en tant que matière active |
Non-Patent Citations (1)
Title |
---|
VAN DER MEY ET AL.: "Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 10, 2003, pages 2008 - 2016, XP008126345 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012512192A (ja) * | 2008-12-19 | 2012-05-31 | レオ ファーマ アクティーゼルスカブ | 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体 |
WO2010117926A1 (en) * | 2009-04-07 | 2010-10-14 | Schering Corporation | Substituted triazolopyridines and analogs thereof |
TWI397530B (zh) * | 2009-04-07 | 2013-06-01 | Merck Sharp & Dohme | 經取代的三唑并吡啶及其類似物 |
US8685967B2 (en) | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
EP2719686A1 (en) * | 2010-03-12 | 2014-04-16 | Nippon Soda Co., Ltd. | Process to halogenate a picoline derivative |
US8841458B2 (en) | 2010-03-12 | 2014-09-23 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
US8962848B2 (en) | 2010-03-12 | 2015-02-24 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
US9000178B2 (en) | 2010-03-12 | 2015-04-07 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
US9012653B2 (en) | 2010-03-12 | 2015-04-21 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
US9018385B2 (en) | 2010-03-12 | 2015-04-28 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
JP2019506432A (ja) * | 2016-03-04 | 2019-03-07 | 大塚製薬株式会社 | 5−メチル−6−フェニル−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 |
US10611731B2 (en) | 2016-03-04 | 2020-04-07 | Otsuka Pharmaceutical Co., Ltd. | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008156094A1 (ja) | 2010-08-26 |
EP2168959A1 (en) | 2010-03-31 |
CA2692248A1 (en) | 2008-12-24 |
US20100160335A1 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008156094A1 (ja) | ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 | |
WO2006053255A3 (en) | Novel betulin derivatives, preparation thereof and use thereof | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
WO2009082152A3 (en) | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | |
WO2009107850A3 (en) | Fused heterocyclic derivative and use thereof | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
WO2009060835A8 (ja) | 新規ユビキリン結合性小分子 | |
WO2008011130A8 (en) | Amide compounds | |
WO2009016460A3 (en) | Pyrazole compounds and their use as raf inhibitors | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
WO2007072153A3 (en) | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | |
WO2008096841A1 (ja) | 二量化シクロ誘導体 | |
WO2006100082A3 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
WO2009082134A3 (en) | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent | |
WO2009051119A1 (ja) | ピリミジルインドリン化合物 | |
WO2005085236A3 (en) | Caspase inhibitors and uses thereof | |
WO2007017728A3 (en) | Novel heterocyclic compounds | |
WO2009020137A1 (ja) | アミノピラゾールアミド誘導体 | |
MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
WO2007064719A3 (en) | Formulations of quinolinones | |
WO2008153129A1 (ja) | 尿酸値低下剤 | |
WO2007099171A3 (en) | Bicyclo-pyrazoles active as kinase inhibitors | |
WO2009051223A1 (ja) | 白内障処置のための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08765704 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009520496 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2692248 Country of ref document: CA Ref document number: 2008765704 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12452172 Country of ref document: US |